Hostname: page-component-7c8c6479df-94d59 Total loading time: 0 Render date: 2024-03-28T18:23:01.645Z Has data issue: false hasContentIssue false

Tailoring Treatment of Depression for Women Across the Reproductive Lifecycle: The Importance of Pregnancy, Vasomotor Symptoms, and Other Estrogen-Related Events in Psychopharmacology

Published online by Cambridge University Press:  07 November 2014

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Trends in Psychopharmacology
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Stahl, SM. Antidepressants. In: Stahl's Essential Psychopharmacology. 3rd ed. New York, NY: Cambridge University Press; 2008:511666.Google Scholar
2.Stahl, SM. Novel therapeutics for depression: L-methylfolate as a trimonoamine modulator and antidepressant-augmenting agent. CNS Spectr. 2007;12:739744.Google Scholar
3.Stahl, SM. Sex-specific and sexual function-related psychopharmacology. In: Essential Psychopharmacology. 2nd.New York, NY: Cambridge University Press; 2000:539568.Google Scholar
4.Stahl, SM. Basic psychopharmacology of antidepressants, part 2: Estrogen as an adjunct to antidepressant treatment. J Clin Psychiatry. 1998;59:1524.Google Scholar
5.Stahl, SM. Natural estrogen as an antidepressant for women. J Clin Psychiatry. 2001;62:404405.Google Scholar
6.Stahl, SM. Effects of estrogen on the central nervous system. J Clin Psychiatry. 2001;62:317318.CrossRefGoogle ScholarPubMed
7.Stahl, SM. Sex and psychopharmacology: is natural estrogen a psychotropic drug in women? Arch Gen Psychiatry. 2001;58:537538.Google Scholar
8.Almeida, OP, Yeap, BB, Hankey, GJ, Jamrozik, K, Flicker, L. Low free testosterone concentration as a potentially treatable cause of depressive symptoms in older men. Arch Gen Psychiatry. 2008;65:283289.Google Scholar
9.Kessler, RC, McGonagle, KA, Swartz, M, Blazer, DG, Nelson, CB. Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence. J Affect Disord. 1993;29:8596.Google Scholar
10.Bebbington, PE, Dunn, G, Jenkins, R, et al.The influence of age and sex on the prevalence of depressive conditions: report from the National Survey of Psychiatric Morbidity. Psychol Med. 1998;28:919.Google Scholar
11.Eaton, WW, Shao, H, Nestadt, G, Lee, BH, Bienvenu, OJ, Zandi, P. Population-based study of first onset and chronicity in major depressive disorder. Arch Gen Psychiatry. 2008;65:513520.Google Scholar
12.McCoy, SJ, Beal, JM, Saunders, B, Hill, EN, Payton, ME, Watson, GH. Risk factors for postpartum depression: a retrospective investigation. J Reprod Med. 2008;53:166170.Google Scholar
13.Cohen, LS, Soares, CN, Vitonis, AF, Otto, MW, Harlow, BL. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry. 2006;63:385390.Google Scholar
14.Freeman, EW, Sammel, MD, Liu, L, Gracia, CR, Nelson, DB, Hollander, L. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry. 2004;61:6270.Google Scholar
15.Freeman, EW, Sammel, MD, Lin, H, Nelson, DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry. 2006;63:375382.Google Scholar
16.Murphy, DD, Cole, NB, Segal, M. Brain-derived neurotrophic factor mediates estradiol-induced dendritic spine formation in hippocampal neurons. Proc Natl Acad Sci USA. 1998;95:1141211417.Google Scholar
17.Zhou, J, Zhang, HB, Cohen, RS, Pandey, SC. Effects of estrogen treatment on expression of brain-derived neurotrophic factor and cAMP response element-binding protein expression and phosphorylation in rat amygdaloid and hippocampal structures. Neuroendocrinology. 2005;81:294310.Google Scholar
18.Frodl, T, Schaub, A, Banac, S, et al.Reduced hippocampal volume correlates with executive dysfunctioning in major depression. J Psychiatry Neurosci. 2006;31:316323.Google Scholar
19.Mayberg, HS, Liotti, M, Brannan, SK, et al.Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry. 1999;156:675682.Google Scholar
20.Wagner, G, Sinsel, E, Sobanski, T, et al.Cortical inefficiency in patients with unipolar depression: an event-related FMRI study with the Stroop task. Biol Psychiatry. 2006;59:958965.Google Scholar
21.Osterlund, MK, Keller, E, Hurd, YL. The human forebrain has discrete estrogen receptor alpha messenger RNA expression: high levels in the amygdaloid complex. Neuroscience. 2000;95:333342.Google Scholar
22.Frye, CA, Walf, AA. Estrogen and/or progesterone administered systemically or to the amygdala can have anxiety-, fear-, and pain-reducing effects in ovariectomized rats. Behav Neurosci. 2004;118:306313.Google Scholar
23.Fava, M, Alpert, JE, Carmin, CN, et al.Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med. 2004;34:12991308.Google Scholar
24.Woolley, CS, Gould, E, Frankfurt, M, McEwen, BS. Naturally occurring fluctuation in dendritic spine density on adult hippocampal pyramidal neurons. J Neurosci. 1990;10:40354039.Google Scholar
25.Woolley, CS, McEwen, BS. Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rat. J Neurosci. 1992;12:25492554.Google Scholar
26.Smith, LJ, Henderson, JA, Abell, CW, Bethea, CL. Effects of ovarian steroids and raloxifene on proteins that synthesize, transport, and degrade serotonin in the raphe region of macaques. Neuropsychopharmacology. 2004;29:20352045.Google Scholar
27.Di Paolo, T, Diagle, M, Picard, V, Barden, N. Effect of acute and chronic 17 beta-estra-diol treatment on serotonin and 5-hydroxyindole acetic acid content of discrete brain nuclei of ovariectomized rat. Exp Brain Res. 1983;51:7376.Google Scholar
28.Le Saux, M, Di Paolo, T. Changes in 5-HT1A receptor binding and G-protein activation in the rat brain after estrogen treatment: comparison with tamoxifen and raloxifene. J Psychiatry Neurosci. 2005;30:110117.Google Scholar
29.Robichaud, M, Debonnel, G. Oestrogen and testosterone modulate the firing activity of dorsal raphe nucleus serotonergic neurones in both male and female rats. J Neuroendocrinol. 2005;17:179185.Google Scholar
30.Kugaya, A, Epperson, CN, Zoghbi, S, et al.Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. Am J Psychiatry. 2003;160:15221524.Google Scholar
31.Pau, KY, Hess, DL, Kohama, S, Bao, J, Pau, CY, Spies, HG. Oestrogen upregulates noradrenaline release in the mediobasal hypothalamus and tyrosine hydroxylase gene expression in the brainstem of ovariectomized rhesus macagues. J Neuroendocrinol. 2000;12:899909.CrossRefGoogle Scholar
32.Kurose, Y, Terashima, Y. Histamine regulates food intake through modulating nor adrenaline release in the para-ventricular nucleus. Brain Res. 1999;828:115118.Google Scholar
33.Etgen, AM. Intrahypothalamic implants of noradrenergic antagonists disrupt lordosis behavior in female rats. Physiol Behav. 1990;48:3136.Google Scholar
34.Vetrivelan, R, Mallick, HN, Kumar, VM. Tonic activity of alpha1 adrenergic receptors of the medial preoptic area contributes towards increased sleep in rats. Neuroscience. 2006;139:11411151.Google Scholar
35.Stahl, SM, Zhang, L, Damatarca, C, Grady, M. Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J Clin Psychiatry. 2003;64(suppl 14):617.Google Scholar
36.Thompson, TL, Moss, RL. Modulation of mesolimbic dopaminergic activity over the rat estrous cycle. Neurosci Lett. 1997;229:145148.Google Scholar
37.Dykens, JA, Wersinger, C, Sidhu, A. 17 beta- and 17 alpha-estradiol are non-competitive inhibitors of dopamine uptake: Implications for Parkinson's disease models and therapeutics. Drug Dev Res. 2005;66:160171.Google Scholar
38.Namba, H, Sokoloff, L. Acute administration of high doses of estrogen increases glucose utilization throughout brain. Brain Res. 1984;291:391394.Google Scholar
39.Cheng, CM, Cohen, M, Wang, J, Bondy, CA. Estrogen augments glucose transporter and IGF1 expression in primate cerebral cortex. FASEB J. 2001;15:907915.Google Scholar
40.Shi, J, Simpkins, JW. 17 bata-Estradiol modulation of glucose transporter 1 expression in blood-brain barrier. Am J Physiol. 1997;272(6 pt 1 ):E1016E1022.Google Scholar
41.Richmond, TK, Rosen, DS. The treatment of adolescent depression in the era of the black box warning. Curr Opin Pediatr. 2005;17:466472.Google Scholar
42.Rapkin, AJ, Winer, SA. The pharmacologic management of premenstrual dysphoric disorder. Expert Opin Pharmacother. 2008;9:429445.CrossRefGoogle ScholarPubMed
43.Cohen, LS, Altshuler, LL, Harlow, BL, et al.Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295:499507.Google Scholar
44.Bar-Oz, B, Einarson, T, Einarson, A, et al.Paroxetine and congenital malformations: Meta-analysis and consideration of potential confounding factors. Clin Ther. 2007;29:918926.Google Scholar
45.Chambers, CD, Hernandez-Diaz, S, Van Marter, LJ, et al.Selective serotonin reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. New Engl J Med. 2006;354:579587.Google Scholar
46.Sanz, EJ, De-las-Cuevas, C, Kiuru, A, Bate, A, Edwards, R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005;365:482487.Google Scholar
47.Davis, RL, Rubanowice, D, McPhillips, H, et al.Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Safety. 2007;16:10861094.Google Scholar
48.Bennett, HA, Einarson, A, Taddio, A, Koren, G, Einarson, TR. Depression during pregnancy: overview of clinical factors. Clin Drug Invest. 2004;24:157179.Google Scholar
49.Seyfried, LS, Marcus, SM. Postpartum mood disorders. Int Rev Psychiatry. 2003;15:231242.Google Scholar
50.Wisner, KL, Wheeler, SB. Prevention of recurrent postpartum major depression. Hosp Community Psychiatry. 1994;45:11911196.Google Scholar
51.McKinlay, SM, Brambilla, DJ, Posner, JG. The normal menopause transition. Maturitas. 1992;14:103115.Google Scholar
52.Soules, MR, Sherman, S, Parrott, E, et al.Executive summary: Stages of Reproductive Aging Workshop (STRAW). Climacteric. 2001;4:267272.Google Scholar
53.Joffe, H, Hall, JE, Soares, CN, et al.Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. Menopause. 2002;9:392398.Google Scholar
54.Bromberger, JT, Meyer, PM, Kravitz, HM, et al.Psychologic distress and natural menopause: a multiethnic community study. Am J Public Health. 2001;91:14351442.Google Scholar
55.Schmidt, PJ, Haq, N, Rubinow, DR. A longitudinal evaluation of the relationship between reproductive status and mood in perimenopausal women. Am J Psychiatry. 2004;161:22382244.Google Scholar
56.Rapkin, AJ. Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment. Am J Obstet Gynecol. 2007;196:97106.CrossRefGoogle ScholarPubMed
57.Myers, RD, Yaksh, TL. Control of body temperature in the unanaesthetized monkey by cholinergic and aminergic systems in the hypothalamus. J Physiol. 1969;202:483500.Google Scholar
58.Soares, CN, Arsenio, H, Joffe, H, et al.Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life. Menopause. 2006;13:780786.Google Scholar
59.Soares, CN, Almeida, OP, Joffe, H, Cohen, LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2001;58:529534.Google Scholar
60.Morrison, MF, Kallan, MJ, Ten, HT, Katz, I, Tweedy, K, Battistini, M. Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. Biol Psychiatry. 2004;55:406412.Google Scholar
61.Archer, DF, DuPont, C, Constantine, G, Pickar, J, Olivier, S. Desvenlafaxine succinate (DVS), a novel serotonin and norepinephrine reuptake inhibitor, improves mood and menopausal symptoms in women with hot flushes (HFS) associated with menopause. Fertil Steril. 2007;88:S246.Google Scholar
62.Joffe, H, Soares, CN, Petrillo, LF, et al.Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine. J Clin Psychiatry. 2007;68:943950.Google Scholar
63.Speroff, L, Gass, M, Constantine, G, Olivier, S. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol. 2008;111:7787.Google Scholar
64.Ladd, CO, Newport, DJ, Ragan, KA, Loughhead, A, Stowe, ZN. Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression. Depress Anxiety. 2005;22:9497.Google Scholar
65.Kornstein, SG, Schatzberg, AF, Thase, ME, et al.Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry. 2000;157:14451452.Google Scholar
66.Martenyi, F, Dossenbach, M, Mraz, K, Metcalfe, S. Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur Neuropsychopharmacol. 2001;11:227232.CrossRefGoogle ScholarPubMed
67.Thase, ME, Entsuah, R, Cantillon, M, Kornstein, SG. Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. J Womens Health (Larchmt). 2005;14:609616.Google Scholar
68.Burt, VK, Wohlreich, MM, Mallinckrodt, CH, Detke, MJ, Watkin, JG, Stewart, DE. Duloxetine for the treatment of major depressive disorder in women ages 40 to 55 years. Psychosomatics. 2005;46:345354.Google Scholar
69.Dormire, SL, Reame, NK. Menopausal hot flash frequency changes in response to experimental manipulation of blood glucose. Nurs Res. 2003;52:338343.Google Scholar
70.Rasgon, NL, Dunkin, J, Fairbanks, L, et al.Estrogen and response to sertraline in postmenopausal women with major depressive disorder: a pilot study. J Psychiatr Res. 2007;41:338343.Google Scholar